NCT05909527View on ClinicalTrials.gov

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions
T-Cell Acute Lymphocytic Leukemia
Interventions
BIOLOGICAL

CD7 CAR-T

A single infusion of autologous CD7 CAR-T cells administered intravenously

Trial Locations (1)

065000

Hebei Yanda Hospital, Langfang

All Listed Sponsors
lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY